Literature DB >> 7586807

Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.

H K Lau1, M Kim, J Koo, B Chiu, D Murray.   

Abstract

Proteolytic activity is important for tumor growth and metastasis. Plasminogen and urokinase-type plasminogen activator (u-PA) constitute one of the most extensively studied proteolytic systems believed to participate in these processes. u-PA cleaves plasminogen to plasmin, which in turn degrades surrounding extracellular matrix and allows tumor cells to migrate to other areas. The specific receptor for u-PA (u-PAR) has also been implicated as an essential modulator in this pathway. Eleven paired samples of colorectal cancers and normal mucosal tissues from the same patients were removed at surgery. The tissues were homogenized and the supernatants assayed for u-PAR immunoreactivity, u-PAR antigen concentration, u-PAR binding activity and u-PA activity. Immunoblot analysis showed that a major u-PAR species of approximately 55 kDa was present in all tissues. In addition, a protein band of approximately 41 kDa, which crossreacted with anti-u-PAR antibodies, was also found in the tumors. This protein band was either absent, or present in relatively small amounts in the normal colorectal tissues. Cross-linking experiments showed that the approximately 55 kDa band only, and not the approximately 41 kDa band, was able to bind either single chain urokinase-type plasminogen activator (scu-PA) or the amino terminal fragment of urokinase (ATF). The tumor samples also exhibited highly elevated u-PA activity and u-PAR antigen relative to the corresponding normal tissues. Elevated u-PA activity appeared to correlate with elevated u-PAR antigen in colorectal cancers, but not in the normal tissues. These increases were also associated with increase of the u-PAR-related, low-molecular-weight protein in the tumor samples. The measurement of u-PAR and the u-PAR-related protein, in addition to u-PA activity, could have diagnostic or prognostic value in this type of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586807     DOI: 10.1007/BF00118188

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

1.  Characterization of urokinase receptor expression by human placental trophoblasts.

Authors:  J M Zini; S C Murray; C H Graham; P K Lala; K Karikó; E S Barnathan; A Mazar; J Henkin; D B Cines; K R McCrae
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

2.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Soluble urokinase receptor from fibrosarcoma HT-1080 cells.

Authors:  H K Lau; M Kim
Journal:  Blood Coagul Fibrinolysis       Date:  1994-08       Impact factor: 1.276

5.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.

Authors:  C Pyke; P Kristensen; E Ralfkiaer; J Grøndahl-Hansen; J Eriksen; F Blasi; K Danø
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.

Authors:  N Behrendt; M Ploug; L Patthy; G Houen; F Blasi; K Danø
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

7.  Differential protease expression by cutaneous squamous and basal cell carcinomas.

Authors:  A P Sappino; D Belin; J Huarte; S Hirschel-Scholz; J H Saurat; J D Vassalli
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

8.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Authors:  H E Mulcahy; M J Duffy; D Gibbons; P McCarthy; N A Parfrey; D P O'Donoghue; K Sheahan
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

9.  Transcriptional activation of the urokinase receptor gene in invasive colon cancer.

Authors:  H Wang; J Skibber; J Juarez; D Boyd
Journal:  Int J Cancer       Date:  1994-09-01       Impact factor: 7.396

10.  Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Authors:  C Bouchet; F Spyratos; P M Martin; K Hacène; A Gentile; J Oglobine
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  3 in total

1.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

2.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

3.  A comparative study of the effects of genistein and 2-methoxyestradiol on the proteolytic balance and tumour cell proliferation.

Authors:  I Fajardo; A R Quesada; I Núñez de Castro; F Sánchez-Jiménez; M A Medina
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.